Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


6 Items
Title  Creator  Group name  Publishing year 
Cytoplasmic PPAR? is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers Shao et al. EquipeVC 2020-02-21
Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor ?1 Are Inversely Associated with Survival in Primary Breast Cancer Shao et al. EquipeVC 2020-01-03
The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status Jeschke et al. EquipeVC Feb 26, 2019
Prognostic relevance of RIP140 and ER? expression in unifocal versus multifocal breast cancers: a preliminary report Müller et al. EquipeVC Jan 18, 2019
Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer Vattai et al. EquipeVC Dec 01, 2017
Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium Obermayr et al. EquipeCTCS Dec 05, 2017
6 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés